MPHSF 财务： Memphasys Limited AI 分析

Q: Memphasys Limited 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Memphasys Limited 的总资产为 $11，净损失为 $-5

Q: MPHSF 的关键财务比率是什么？

Memphasys Limited 的流动比率是 1.83，净利 margin 为 0，每股销售为 $0。

Q: Memphasys Limited 的收入按细分市场或地理位置如何划分？

Memphasys Limited 最大收入来源是 Reproductive Technologies，在最近的收益报告中收入为 60,000。就地区而言， Australia 是 Memphasys Limited 的主要市场，收入为 60,000。

Q: Memphasys Limited 是否盈利？

不，根据最新的财务报表，Memphasys Limited 的净损失为 $-5

Q: Memphasys Limited 有负债吗？

是的，Memphasys Limited 的负债为 6

Q: Memphasys Limited 的流通股有多少？

Memphasys Limited 的总流通股为 2,082.73

主页

股票

MPHSF

MPHSF 财务

Memphasys Limited

0%

$0

收盘价：Feb 13, 16:00:00 GMT-5

0%

$0

盘后：Feb 13, 20:00:00 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

开盘价

当日区间

52周范围

交易量

平均成交量

每股收益（TTM）

股息收益率

市值

什么是 MPHSF？

Memphasys Ltd. is a life sciences company, which engages in the development and commercialization of novel reproduction and fertility solutions for humans and animals. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The firm is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The firm's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.

功能特性

资源

市场

收入

资产负债表

现金流量

年度

季度性

MPHSF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
营收	0	0	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	--
营收成本	0	0	0	0	0	--
毛利润	0	0	0	0	0	--
销售、一般及管理费用	1	1	1	1	1	1
研发	1	1	2	1	1	0
营业费用	3	3	5	3	1	1
其他非经营性收入 (费用)	--	--	0	0	0	--
税前利润	-5	-5	-5	-3	-2	-1
所得税费用	--	0	0	0	0	0
净利润	-5	-5	-5	-3	-2	-1
净利润增长	0%	0%	67%	50%	100%	0%
稀释后流通股数	5,404.38	3,521.97	2,425.94	1,062.62	867.09	836.51
股份同比变动 (YoY)	41%	45%	128%	23%	4%	6%
每股收益 (摊薄)	0	0	0	0	0	0
每股收益增长率	-31%	-36%	-31%	33%	33%	28.99%
自由现金流	-3	-3	-3	-3	-2	-2
每股自由现金流	--	--	--	--	--	--
毛利率	0%	0%	0%	0%	0%	--
营业利润率	0%	0%	0%	0%	0%	0%
净利率	0%	0%	0%	0%	0%	0%
自由现金流利润率	0%	0%	0%	0%	0%	0%
EBITDA	-3	-3	-5	-3	-1	--
EBITDA 利润率	0%	0%	0%	0%	0%	--
EBITDA 中的折旧与摊销	0	0	0	0	0	--
EBIT	-3	-3	-5	-3	-1	-1
EBIT 利润率	0%	0%	0%	0%	0%	0%
有效税率	--	0%	0%	0%	0%	0%

Follow-Up Questions

Memphasys Limited 的关键财务报表是什么？



MPHSF 的关键财务比率是什么？



Memphasys Limited 的收入按细分市场或地理位置如何划分？



Memphasys Limited 是否盈利？



Memphasys Limited 有负债吗？



Memphasys Limited 的流通股有多少？



Memphasys Limited（MPHSF）价格

MPHSF 股价走势图